D'Amico classified patients with localized prostate cancer into risk groups based on clinical and laboratory findings. The risk group can be helpful in guiding patient management. The authors are from Harvard Medical School, University of Pennsylvania, University of Millersville (Pennsylvania) and Brigham and Women's Hospital.
